Lqttrx
Founded 2019 · 34 employees on LinkedIn · 1 known investors
Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases. Its lead compound, THRV-1268, is in a Phase 2/3 clinical study for Long QT Syndrome Type 2.
Investors · 1
Frequently asked questions
- What does Lqttrx do?
- Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases. Its lead compound, THRV-1268, is in a Phase 2/3 clinical study for Long QT Syndrome Type 2.
- Who are Lqttrx's investors?
- Lqttrx's investors include Amzak Health.